The estimated Net Worth of Alex Sapir is at least $13.6 Tisíc dollars as of 3 July 2024. Mr. Sapir owns over 150,000 units of PhaseBio Pharmaceuticals stock worth over $13,555 and over the last 7 years he sold PHAS stock worth over $0. In addition, he makes $0 as Independent Director at PhaseBio Pharmaceuticals.
Sign up
Mr. Sapir PHAS stock SEC Form 4 insiders trading
Alex has made over 6 trades of the PhaseBio Pharmaceuticals stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 150,000 units of PHAS stock worth $490,500 on 3 July 2024.
The largest trade he's ever made was exercising 150,000 units of PhaseBio Pharmaceuticals stock on 3 July 2024 worth over $490,500. On average, Alex trades about 26,572 units every 256 days since 2017. As of 3 July 2024 he still owns at least 193,360 units of PhaseBio Pharmaceuticals stock.
You can see the complete history of Mr. Sapir stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alex Sapir biography
Alex C. Sapir serves as Independent Director of the Company. Mr. Sapir has served as chief executive officer and a member of the board of directors of ReViral Ltd. since June 2019. Mr. Sapir served as the president and chief executive officer of Dova Pharmaceuticals Inc. from January 2017 to December 2018 and as a member of the board of directors from March 2017 to April 2019. From 2006 to 2016, Mr. Sapir served as executive vice president, marketing and sales for United Therapeutics Corporation. Mr. Sapir received a B.A. in economics from Franklin and Marshall College and an M.B.A. from Harvard Business School. Our Board of Directors believes that Mr. Sapir is qualified to serve as a director because of his extensive pharmaceutical experience, including with respect to sales and marketing.
What's Alex Sapir's mailing address?
Alex's mailing address filed with the SEC is C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139.
Insiders trading at PhaseBio Pharmaceuticals
Over the last 6 years, insiders at PhaseBio Pharmaceuticals have traded over $361,083 worth of PhaseBio Pharmaceuticals stock and bought 24,000 units worth $81,960 . The most active insiders traders include Clay Thorp, Enterprise Associates 13 Lp... a Nancy J Hutson. On average, PhaseBio Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $5,138. The most recent stock trade was executed by Clay Thorp on 19 May 2023, trading 3,750 units of PHAS stock currently worth $263.
What does PhaseBio Pharmaceuticals do?
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
What does PhaseBio Pharmaceuticals's logo look like?
Complete history of Mr. Sapir stock trades at Fulcrum Therapeutics Inc a PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals executives and stock owners
PhaseBio Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Jonathan Mow,
Chief Executive Officer, Director -
Jonathan P. Mow,
Pres, CEO & Director -
John Lee,
Chief Medical Officer -
John Sharp,
Chief Financial Officer -
Dr. John S. Lee,
Chief Medical Officer -
John P. Sharp,
Chief Financial Officer -
Clay Thorp,
Co-Founder, Independent Chairman of the Board -
Peter Klein,
Independent Director -
Nancy Hutson,
Independent Director -
Richard van den Broek,
Independent Director -
Caroline Loewy,
Independent Director -
Edmund Harrigan,
Independent Director -
Alex Sapir,
Independent Director -
Michael York,
Vice President - Corporate Development and Commercial Strategy -
Jim Ballance,
Vice President - Research and Scientific Affairs -
Susan Arnold,
Vice President - Preclinical and Chemistry, Manufacturing and Controls -
Kristophe Hanson,
Vice President - Head of Legal, Corporate Secretary -
Glen Burkhardt,
Vice President - Human Resources -
Jonathan J. Birchall,
Chief Commercial Officer -
Glen Burkhardt,
VP of HR -
Lauren Richardson,
Global Head of Regulatory Affairs & Quality Assurance -
Kristopher L. Hanson,
VP, Head of Legal & Corp. Sec. -
Bibhash Mukhopadhyay,
Director -
David James Ballance,
VP, Research and Sci. Affairs -
Linda Tufts,
Director -
William D. Humphries,
Director -
Jonathan Birchall,
Chief Commercial Officer -
Enterprise Associates 13 Lp...,